Top Qs
Timeline
Chat
Perspective
Excision BioTherapeutics
American biotechnology company From Wikipedia, the free encyclopedia
Remove ads
Excision BioTherapeutics is a biopharmaceutical company based in San Francisco focused on developing gene therapies against HIV infection.
Remove ads
The company has a single, CRISPR–Cas9 based therapy, EBT-101, under investigation. Initial investigation into the therapy was conducted by the lab of Kamel Khalili, a professor at Temple University.[1][2][3][4] In July 2023 the US Food and Drug Administration granted EBT-101 fast-track status.[5] In October 2023 an early-stage study on 3 people reported that the treatment appeared to be safe with no major side effects but no data on its effectiveness was disclosed.[6]
Remove ads
See also
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads